Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


After Januvia And Onglyza, Novartis Launches Galvus In China; Lucentis Receives SFDA Nod

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis looks to take on Merck’s Januvia in China, noting it will have a level-playing field despite playing catch up in the market with the world’s largest diabetes population.


Related Content

Regeneron Plays It Safe With Eylea, Aims To Undercut Lucentis
Sanofi China GM Fabrice Baschiera On Winning The Insulin Battle In China: An Interview With PharmAsia News (Part 1 of 2)
Lucentis Shines In Diabetic Eye Disease, But Competition Looms From Cheap, Off-Label Avastin
Roche Launches Avastin In China For Colon And Rectal Cancer Following Counterfeit Drug Incident In Shanghai
Merck Sharp & Dohme Launches Januvia In China To Join Race In Second-largest Diabetes Market
Novartis Lines Up $1 Billion For China R&D
Lilly Launches Byetta In China To Target World's Second Largest Diabetes Market


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts